Lymphodepleting chemotherapy (Flu/Cy)

DRUG2 trials

Sponsors

Beijing Biotech

Conditions

Metastatic DiseasePancreatic Ductal Adenocarcinoma (PDAC)Unresectable Locally AdvancedUnresectable Locally Advanced or Metastatic Disease

Phase 1

Dual-Targeting CAR-NK Cells Targeting Mesothelin (MSLN) and MUC1 in Advanced Pancreatic Ductal Adenocarcinoma

RecruitingNCT07480928

Beijing BiotechPancreatic Ductal Adenocarcinoma (PDAC), Unresectable Locally Advanced or Metastatic Disease

Start: 2026-02-02End: 2028-06-26Target: 42Updated: 2026-03-18

Dual-Target CAR-NK Cells Targeting Mesothelin (MSLN) and MUC1 in Advanced Pancreatic Ductal Adenocarcinoma

RecruitingNCT07627711

Beijing BiotechMetastatic Disease, Pancreatic Ductal Adenocarcinoma (PDAC), Unresectable Locally Advanced

Start: 2026-03-02End: 2028-03-17Target: 42Updated: 2026-06-04